- Home
- PHAR vs GGN Comparison
PHAR vs GGN Comparison
Compare PHAR & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- GGN
- Stock Information
- Founded
- PHAR 1988
- GGN 2005
- Country
- PHAR Netherlands
- GGN United States
- Employees
- PHAR N/A
- GGN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- GGN Finance/Investors Services
- Sector
- PHAR Health Care
- GGN Finance
- Exchange
- PHAR Nasdaq
- GGN Nasdaq
- Market Cap
- PHAR 718.1M
- GGN 669.1M
- IPO Year
- PHAR N/A
- GGN N/A
- Fundamental
- Price
- PHAR $11.00
- GGN $4.36
- Analyst Decision
- PHAR Strong Buy
- GGN
- Analyst Count
- PHAR 3
- GGN 0
- Target Price
- PHAR $30.00
- GGN N/A
- AVG Volume (30 Days)
- PHAR 3.0K
- GGN 397.4K
- Earning Date
- PHAR 07-31-2025
- GGN 01-01-0001
- Dividend Yield
- PHAR N/A
- GGN 10.26%
- EPS Growth
- PHAR N/A
- GGN N/A
- EPS
- PHAR N/A
- GGN N/A
- Revenue
- PHAR $320,708,000.00
- GGN N/A
- Revenue This Year
- PHAR $13.31
- GGN N/A
- Revenue Next Year
- PHAR $7.68
- GGN N/A
- P/E Ratio
- PHAR N/A
- GGN N/A
- Revenue Growth
- PHAR 24.13
- GGN N/A
- 52 Week Low
- PHAR $6.65
- GGN $3.51
- 52 Week High
- PHAR $12.61
- GGN $3.91
- Technical
- Relative Strength Index (RSI)
- PHAR 51.11
- GGN 50.00
- Support Level
- PHAR $10.23
- GGN $4.39
- Resistance Level
- PHAR $11.21
- GGN $4.49
- Average True Range (ATR)
- PHAR 0.27
- GGN 0.04
- MACD
- PHAR -0.14
- GGN -0.02
- Stochastic Oscillator
- PHAR 34.01
- GGN 32.35
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.